WASHINGTON (Reuters) - U.S. health regulators have said GlaxoSmithKline Plc's Advair is safe and effective to more widely treat patients with chronic obstructive pulmonary disease (COPD), the ...

GlaxoSmithKline plc (LSE/NYSE:GSK) today announced publication of results from the 'LABA' (long acting beta2-agonist) safety study, AUSTRI (SAS115359) in the New England Journal of Medicine (NEJM).

Advair 250/50 Now the Only Treatment Approved to Both Reduce Exacerbations and Improve Lung Function RESEARCH TRIANGLE PARK, N.C., May 1 -- Late yesterday the U.S. Food and Drug Administration ...

Does the world's bestselling asthma drug sometimes kill the patients it is supposed to help? Frank A. Dittig was recovering from a nasty bout of pneumonia in the spring of 2004 when he developed a ...

Advair is one of the biggest blockbusters in pharmaceutical history. The asthma drug has generated more than $80 billion in global revenues for its maker, GlaxoSmithKline, since its U.S. approval in ...

U.S. regulators gave GlaxoSmithKline's ($GSK) Advair the green light a decade and a half ago, paving the way for a long reign that saw the med grow to more than $8 ...

WALTHAM, Mass., Dec. 1 Decision Resources, one of theworld's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, finds that patient share for GlaxoSmithKline's Advair ...

A strict new warning may impact sales of one of the world's top-selling asthma drugs. GlaxoSmithKline said today it had reached an agreement to update its product label for its popular drug Advair ...

GSK would continue to make Advair inhalers in Zebulon if generic competition emerges this year. It also makes new asthma inhalers and two HIV drugs at its Zebulon facility. Chris Seward ...

The FDA also expanded the use of Advair Diskus 250/50 to a broader patient population which includes not only patients with COPD associated with chronic bronchitis, but also emphysema or both ...